
    
      After being informed about the study and potential risks, all patients giving written
      informed consent will be undergoing a 1-day screening to determine eligibility for study
      entry. At day 1, patients who meet the eligibility requirements will be randomized in a
      double-blind manner (participant and investigator) in a 1:1 ratio to ATR-002 (900mg day 1,
      600mg days 2 - 6) or placebo (once daily)
    
  